RECIST
Pronunciation: REH-sist
Also written as: RECIST — Response Evaluation Criteria in Solid Tumors
Response Evaluation Criteria in Solid Tumors - standardized criteria for measuring tumor response to treatment in cancer trials.
Full Definition
Response Evaluation Criteria in Solid Tumors (RECIST) is a set of published rules that define when cancer patients improve ('respond'), stay the same ('stable'), or worsen ('progression') during treatment. RECIST provides a standardized way to measure these changes using imaging studies. The criteria are essential for clinical trial design and regulatory submissions, establishing consistent endpoints across oncology research. Version 1.1 is currently the most widely used standard in clinical practice.
Usage
Usage note: Always capitalize as RECIST, not Recist. Include version number (e.g., RECIST 1.1) when specificity is required.
In Context
- "The protocol specified RECIST 1.1 criteria for assessing tumor response at 8-week intervals." — Clinical trial protocol
- "Progressive disease was defined according to RECIST guidelines as a 20% increase in target lesion diameter." — Regulatory submission